aTyr Pharma

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. Mission: We understand disease never takes a day off. Our transformational science never sleeps in order to make meaningful medicines. With relentless determination, we discover life-changing therapies for people with grave maladies. We make our medicines by orchestrating important physiological processes in ways that have never been thought of before. We recruit and retain remarkable people to actualize our mission in the form of industry admired results in all aspects of our business.